ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026
Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI).
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesNew treatments for melanoma, such as targeted therapy and immunotherapy, present unique adverse events compared to traditional treatments like surgery and chemotherapy. Existing health-related quality of life (HRQoL) measures often fail to address these new treatment effects and focus primarily on chemotherapy and surgery. This study aimed to develop and validate a new HRQoL instrument for melanoma patients across all tumor stages, encompassing a broader range of adverse events and melanoma-specific aspects. PATIENTS AND
methodsThe Essen Melanoma Quality of Life Inventory (EMQoLI) was tested with 387 German-speaking malignant melanoma patients across all tumor stages.
resultsExploratory factor analysis revealed a three-factor structure. Eight items were removed due to low or cross-loading, leaving a final version of 25 items with satisfactory reliability and internal consistency. Correlation analyses indicated good convergent and discriminant validity.
conclusionsThe EMQoLI is a 25-item German self-report tool based on a 5-point Likert scale, designed to assess HRQoL in melanoma patients across all tumor stages. It offers healthcare professionals an efficient tool to identify patients needing psychosocial support and can serve as a standardized measurement instrument in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.